TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
VYGR

Voyager Therapeutics Inc

Healthcare · Biotechnology

2.50$ -8.4% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Voyager Therapeutics Inc (VYGR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 198 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet VYGR
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
202 190 175 158 141 184 235 215 197 177 411 389 376 355 323 297 270 262 238 209 185 194 224 189 182 159 336 316 295 351 470 436 426 393 353 322 288 252 219 198
193 179 161 145 128 172 221 200 182 162 365 341 328 305 272 247 216 198 176 149 126 137 171 152 147 124 303 282 262 320 409 382 373 277 245 228 220 203 147 125
64 37 44 66 48 32 140 60 42 47 113 80 83 86 165 144 147 104 118 118 111 117 132 78 97 99 268 244 65 69 143 76 113 71 75 44 45 65 43 36
191 174 158 141 126 169 218 196 180 156 358 327 307 282 251 230 200 181 162 143 121 133 167 148 132 119 273 273 253 231 400 371 345 267 236 216 209 196 141 116
– 2.3 2.3 – – 0.1 0.1 – – 0.2 – 10 14 19 16 13 13 8.0 4.3 1.8 1.2 0.7 0.2 0.2 10 0.6 25 3.4 3.3 84 3.5 3.3 20 4.5 2.1 2.5 4.0 1.8 1.6 3.2
0.0 1.5 0.0 0.0 0.0 1.9 0.0 0.0 0.0 5.1 – 0.0 – 2.2 – – 0.0 6.9 0.0 – – 1.7 – 0.0 – 0.8 0.0 0.0 – 0.0 0.0 – – – – – – – – –
4.3 7.9 10 11 11 10 11 12 13 13 43 45 45 46 46 47 23 25 25 58 23 22 19 19 34 18 17 17 – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
53 54 52 53 56 50 137 133 131 131 311 270 268 255 243 221 104 107 102 98 97 99 148 129 103 100 119 117 118 115 129 101 96 93 81 78 68 56 46 43
19 14 11 12 21 16 31 29 30 32 59 69 80 76 73 68 42 27 25 25 27 51 102 98 73 73 20 45 62 65 73 40 44 50 40 42 35 27 17 17
– – – – – – – – – – 9.3 2.8 3.0 3.2 3.3 3.4 3.5 4.2 4.6 4.9 5.2 5.6 5.7 2.5 2.7 2.8 2.9 3.0 3.1 3.2 5.9 6.7 7.0 7.2 7.4 7.6 7.8 7.8 7.4 6.9
0.8 0.6 0.6 0.3 0.9 1.0 1.4 1.6 1.4 1.0 2.3 2.2 4.0 4.1 4.8 2.0 3.4 0.6 3.2 0.8 0.6 0.6 1.2 1.2 1.3 2.6 3.7 1.7 3.3 1.6 7.6 2.6 3.2 4.0 2.6 1.8 2.1 5.0 2.7 1.6
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – – – – – – –
149 136 123 105 85 134 98 82 66 46 101 118 108 100 80 77 166 154 136 111 87 95 76 60 80 59 217 199 176 236 341 335 330 300 273 244 220 196 174 154
-75 -90 -107 -126 -149 -161 -201 -226 -247 -269 -296 -285 -300 -313 -337 -346 -260 -276 -298 -328 -353 -347 -368 -388 -370 -394 -269 -292 -318 -261 -273 -283 -292 -326 -357 -391 -418 -446 -474 -498
25 26 26 26 26 29 32 32 32 32 33 38 37 37 37 37 38 37 38 38 38 38 38 38 40 39 42 44 44 45 57 58 58 58 58 59 59 59 59 61

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?